AMICUS THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Amicus Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Amicus Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$6.73M, a 68.8% increase year-over-year.
  • Amicus Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$105M, a 39.7% increase year-over-year.
  • Amicus Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$152M, a 35.9% increase from 2022.
  • Amicus Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$237M, a 5.55% increase from 2021.
  • Amicus Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$250M, a 9.53% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$105M -$6.73M +$14.8M +68.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$120M -$15.7M +$27.5M +63.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$147M -$48.4M +$4.51M +8.53% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$152M -$33.8M +$22M +39.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$174M -$21.6M +$11.7M +35.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$185M -$43.2M +$18.9M +30.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$204M -$52.9M +$32.3M +37.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$237M -$55.9M +$27.4M +32.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$264M -$33.3M +$17M +33.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$281M -$62.2M -$10.9M -21.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$270M -$85.3M -$19.6M -29.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$250M -$83.3M -$11.9M -16.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$239M -$50.3M +$13.7M +21.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$252M -$51.2M +$1.27M +2.41% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$254M -$65.7M +$23.3M +26.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$277M -$71.4M +$18.3M +20.4% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$295M -$64M -$2.2M -3.56% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$293M -$52.5M +$32.1M +37.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$325M -$88.9M +$31.4M +26.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$356M -$89.7M -$11.6M -14.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$345M -$61.8M +$97.4M +61.2% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$442M -$84.6M -$22.7M -36.7% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$419M -$120M -$70.4M -141% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$349M -$78.1M -$8.88M -12.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$340M -$159M -$47.5M -42.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 -$293M -$61.8M -$13.7M -28.5% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 -$279M -$49.9M +$5.08M +9.23% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
Q4 2017 -$284M -$69.2M -$10.6M -18% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$273M -$112M -$65M -139% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$208M -$48.1M +$2.91M +5.71% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$211M -$55M -$11.3M -25.9% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$200M -$58.6M -$15.8M -36.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$184M -$46.7M -$8.85M -23.4% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$175M -$51.1M -$23.9M -88.1% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$152M -$43.7M -$19.4M -79.9% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 -$132M -$42.9M -$21.7M -102% Oct 1, 2015 Dec 31, 2015 10-K/A 2017-03-03
Q3 2015 -$110M -$37.8M -$20.7M -120% Jul 1, 2015 Sep 30, 2015 10-K/A 2017-03-03
Q2 2015 -$89.8M -$27.1M -$12.5M -85.7% Apr 1, 2015 Jun 30, 2015 10-K/A 2017-03-03
Q1 2015 -$77.3M -$24.3M -$8.35M -52.3% Jan 1, 2015 Mar 31, 2015 10-K/A 2017-03-03
Q4 2014 -$68.9M -$21.2M -$8.98M -73.4% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-29
Q3 2014 -$59.9M -$17.1M -$2.56M -17.5% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-29
Q2 2014 -$57.4M -$14.6M +$735K +4.79% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-29
Q1 2014 -$58.1M -$15.9M +$1.52M +8.68% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-29
Q4 2013 -$59.6M -$12.2M -$2.22M -22.2% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-03
Q3 2013 -$57.4M -$14.6M +$1.7M +10.4% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-03
Q2 2013 -$59.1M -$15.3M -$6.01M -64.3% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-03
Q1 2013 -$53.1M -$17.5M -$4.32M -32.9% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-03
Q4 2012 -$48.8M -$10M -$1.35M -15.6% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-03
Q3 2012 -$47.4M -$16.3M -$6.53M -66.9% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-03
Q2 2012 -$40.9M -$9.34M +$3.3M +26.1% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-03
Q1 2012 -$44.2M -$13.1M +$213K +1.6% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-03
Q4 2011 -$44.4M -$8.66M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-13
Q3 2011 -$9.76M +$5.6M +36.5% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-13
Q2 2011 -$12.6M -$1.33M -11.7% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-13
Q1 2011 -$13.4M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-13
Q3 2010 -$15.4M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-02
Q2 2010 -$11.3M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.